Empagliflozin: all 403 studies that test it

Page 2 of 5. Open to participants first (103), then studies with results posted, then the rest; newest registration first within each.

• Randomised Evaluation of COVID-19 TherapyRecruitingNCT04381936Phase 3
• SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver DiseaseNot yet recruitingNCT03867487Phase 2
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingNCT03424005Phase 1/2
• Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT06435858Phase 2Results posted
• SGLT2 Inhibitor Therapy in Cystic Fibrosis-related DiabetesActive, not recruitingNCT06149793Phase 2/3Results posted
• A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)TerminatedNCT05282121Phase 2Results posted
• A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 DiabetesCompletedNCT05254002Phase 2Results posted
• SGLT2 Inhibitors in Transthyretin Amyloid CardiomyopathyCompletedNCT05233163Phase 4Results posted
• Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes MellitusCompletedNCT05232071Phase 2Results posted
• A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney DiseaseCompletedNCT05182840Phase 2Results posted
• A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered TogetherCompletedNCT05083949Phase 1Results posted
• SNIFF - Combo INI+EMPA TrialCompletedNCT05081219Phase 2Results posted
• SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity PilotCompletedNCT04907214Phase 1/2Results posted
• A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 YearsCompletedNCT04531462Phase 4Results posted
• EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)CompletedNCT04509674Phase 3Results posted
• A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take InsulinCompletedNCT04233801Phase 3Results posted
• A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart FailureCompletedNCT04157751Phase 3Results posted
• Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone ProductionCompletedNCT03852901Phase 1Results posted
• This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate PillsCompletedNCT03629054Phase 1Results posted
• EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)CompletedNCT03594110Phase 3Results posted
• Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).CompletedNCT03485222Phase 4Results posted
• This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure SymptomsCompletedNCT03448419Phase 3Results posted
• This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.CompletedNCT03448406Phase 3Results posted
• Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TMCompletedNCT03429543Phase 3Results posted
• A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take EmpagliflozinCompletedNCT03332212Phase 3Results posted
• This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the BloodCompletedNCT03259490Phase 1Results posted
• SGLT2 Inhibition in Combination With Diuretics in Heart FailureCompletedNCT03226457Phase 4Results posted
• Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart FailureCompletedNCT03200860Phase 2Results posted
• Empagliflozin and Hepatic Glucose MetabolismCompletedNCT03193684Phase 4Results posted
• Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial InfarctionCompletedNCT03087773Phase 3Results posted
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)CompletedNCT03057977Phase 3Results posted
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)CompletedNCT03057951Phase 3Results posted
• Empagliflozin Impact on Hemodynamics in Patients With Heart FailureCompletedNCT03030222Phase 4Results posted
• Visceral Adiposity and Diabetes: Translating Form to Function Using ImagingCompletedNCT02833415Phase 4Results posted
• Empa/Lina FDC Food Effect Study (Japan)CompletedNCT02815644Phase 1Results posted
• Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female SubjectsCompletedNCT02758171Phase 1Results posted
• Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN StudyCompletedNCT02632747Phase 2Results posted
• Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes MellitusCompletedNCT02589639Phase 4Results posted
• Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RACompletedNCT02589626Phase 4Results posted
• Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)CompletedNCT02580591Phase 3Results posted
• Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed ConditionsCompletedNCT02577315Phase 1Results posted
• Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes MellitusCompletedNCT02489968Phase 3Results posted
• Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)CompletedNCT02414958Phase 3Results posted
• Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and FemaleCompletedNCT02266472Phase 1Results posted
• Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy SubjectsCompletedNCT02230995Phase 1Results posted
• Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single TabletsCompletedNCT02106923Phase 1Results posted
• Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese VolunteersCompletedNCT02102932Phase 1Results posted
• Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate TabletsCompletedNCT02028767Phase 1Results posted
• Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single TabletsCompletedNCT01975220Phase 1Results posted
• Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes MellitusCompletedNCT01947855Phase 3Results posted
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 TabletsCompletedNCT01924767Phase 1Results posted
• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal ImpairmentCompletedNCT01907113Phase 1Results posted
• Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy ControlsCompletedNCT01867307Phase 2Results posted
• Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single TabletsCompletedNCT01844531Phase 1Results posted
• Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered TogetherCompletedNCT01811953Phase 1Results posted
• Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 DiabetesCompletedNCT01778049Phase 3Results posted
• Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 DiabetesCompletedNCT01734785Phase 3Results posted
• Demonstration of Bioequivalence of Empagliflozin and Metformin Given in One Tablet Compared to the Intake of Single TabletsCompletedNCT01672788Phase 1Results posted
• A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin TherapyCompletedNCT01649297Phase 2Results posted
• Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and ProbenecidCompletedNCT01634100Phase 1Results posted
• Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 DiabetesCompletedNCT01581658Phase 1Results posted
• Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet as Well as Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets Under Fasting Conditions.CompletedNCT01451775Phase 1Results posted
• Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes PatientsCompletedNCT01422876Phase 3Results posted
• Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal HyperfiltrationCompletedNCT01392560Phase 2Results posted
• 12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes MellitusCompletedNCT01370005Phase 3Results posted
• Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes MellitusCompletedNCT01368081Phase 3Results posted
• Drug-drug Interaction of Empagliflozin (BI 10773) and MicrogynonCompletedNCT01328184Phase 1Results posted
• Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes MellitusCompletedNCT01316341Phase 1Results posted
• Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes MellitusCompletedNCT01306214Phase 3Results posted
• Drug Interaction Study of Digoxin and BI 10773CompletedNCT01306175Phase 1Results posted
• Drug-drug Interaction of Empagliflozin (BI 10773) and SimvastatinCompletedNCT01304329Phase 1Results posted
• Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 DiabetesCompletedNCT01289990Phase 3Results posted
• Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy VolunteersCompletedNCT01284621Phase 1Results posted
• DDI Between BI Empagliflozin (10773) and VerapamilCompletedNCT01276301Phase 1Results posted
• Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 DiabetesCompletedNCT01276288Phase 1Results posted
• A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy SubjectsCompletedNCT01248364Phase 2Results posted
• Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female VolunteersCompletedNCT01242176Phase 1Results posted
• Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With MetforminCompletedNCT01210001Phase 3Results posted
• Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male SubjectsCompletedNCT01195675Phase 1Results posted
• Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes MellitusCompletedNCT01193218Phase 2Results posted
• Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of FoodCompletedNCT01189201Phase 1Results posted
• Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 DiabetesCompletedNCT01177813Phase 3Results posted
• Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 DiabetesCompletedNCT01167881Phase 3Results posted
• Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal ImpairmentCompletedNCT01164501Phase 3Results posted
• Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 DiabetesCompletedNCT01159600Phase 3Results posted
• BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).CompletedNCT01131676Phase 3Results posted
• Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy VolunteersCompletedNCT01111331Phase 1Results posted
• Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver FunctionCompletedNCT01111318Phase 1Results posted
• Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 DiabetesCompletedNCT01011868Phase 2Results posted
• 4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)CompletedNCT00885118Phase 2Results posted
• Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label ExtensionCompletedNCT00881530Phase 2Results posted
• 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic PatientsCompletedNCT00789035Phase 2Results posted
• BI 10773 add-on to Metformin in Patients With Type 2 DiabetesCompletedNCT00749190Phase 2Results posted
• 4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 DiabetesCompletedNCT00558571Phase 1Results posted
• Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release TabletsCompletedNCT07872358Phase 1
• ELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy AgingCompletedNCT07871799Phase 2
• Comparing The Effect Of Empagliflozin With Dapagliflozin In Reducing Proteinuria In Diabetic Patients With Chronic Kidney Disease With eGFR More Than 45ml/Min/1.73m²CompletedNCT07866235Not applicable
• Bioequivalence Study to Compare Empagliflozin/ Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mgCompletedNCT07694115Phase 1
• Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release TabletsCompletedNCT07691203Phase 1
• SGLT2 Adjunct in T1DCompletedNCT07591077Phase 2/3

← Empagliflozin overview